AKTX Akari Therapeutics Plc - American Depositary Shares
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 13, 2026
$8,72
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$0,13minimo 52 sett.
$29,32massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$1.22T
EPS
$0.00
i tuoi badge
Intervallo 52 sett.
$0–$29
Rating Analisti
BUY
Prezzo Obiettivo
$26
P/E
·
ROE
-64.1%
Margine di Profitto Netto
·
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
AKTX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$8.72
Capitalizzazione di Mercato (MRQ)
$1.22T
EPS
$0.00
ROE
-64.1%
D/E Debito/Patrimonio
0.0
Intervallo 52 sett.
$0–$29
AKTX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Split azionari
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 31 Marzo 2026 | 1-for-40 | Inverso |
| 17 Agosto 2023 | 1-for-20 | Inverso |
| 17 Settembre 2015 | 1-for-10 | Inverso |
| 03 Gennaio 2014 | 1-for-5 | Inverso |
Performance decennale Andamento di ricavi, utile netto, margini e EPS
EPS$0.002022-12-31 → 2025-12-31
Flusso di cassa libero·2014-12-31 → 2015-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | AKTX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/B (MRQ) | 65667.4media 5 anni ≈-42364.4 | ≈-42364.4 | 5.2 | Sopravvalutato | |
| EV / EBITDA | -45700.8 | · | · | · | |
| Price / Cash Flow (Prezzo / Flusso di cassa) | -74704.9media 5 anni ≈-19734.5 | ≈-19734.5 | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 39676.4 | · | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | AKTX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| ROA | -35.1%media 5 anni ≈-85.2% | ≈-85.2% | -81.5% | Di prim'ordine | |
| ROE | -64.1%media 5 anni ≈31150.8% | ≈31150.8% | -113.8% | Di prim'ordine | |
| ROIC | -57.5%media 5 anni ≈1781.0% | ≈1781.0% | · | · |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | AKTX | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debt / Equity (Debito / Patrimonio Netto) | 0.0 | · | · | · | |
| Rapporto corrente (MRQ) | 0.6media 5 anni ≈1.3 | ≈1.3 | 1.7 | Bassa liquidità | |
| Quick Ratio | 0.0media 5 anni ≈1.1 | ≈1.1 | 1.3 | Bassa liquidità | |
| Interest Coverage (Copertura degli interessi) | -172.8 | · | · | · |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Nessun dato per questo gruppo di rapporti al momento
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Nessun dato per questo gruppo di rapporti al momento
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
36.6%
Prossimo report
Nov 11, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 13, 2026 | $-2.68 | $-1.31 | -105.3% |
| 31 Marzo 2026 | Mag 19, 2026 | $-1.57 | $-1.40 | -11.8% |
| 31 Dicembre 2025 | $0.00 | $-1.53 | 100.0% | |
| 30 Settembre 2025 | $0.00 | $-3.13 | 100.0% | |
| 30 Giugno 2025 | $0.00 | $-4.69 | 100.0% | |
| 31 Marzo 2021 | $0.00 | $0.00 | — | |
| 31 Marzo 2020 | $-2.60 | $0.00 | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| R&D Expense | $3M | $7M | $5M | $10M | $6M | $2M | $1M | |
| SG&A Expense | $9M | $10M | $11M | $14M | $6M | $303.1K | $2M | |
| Operating Expenses | $17M | $22M | $17M | · | $31M | $2M | · | |
| Operating Income | $-17M | $-22M | $-17M | $-23M | $-31M | $-2M | $-4M | |
| Interest Expense | $100.0K | · | · | · | $3M | $5.4K | · | |
| Interest Income | $1.0K | $8.0K | $82.0K | $46.0K | $20.7K | $91 | · | |
| Other Non-op | $-1M | $2M | $-19.0K | $-142.0K | $-15M | $-28.3K | $-14.0K | |
| Pretax Income | $-18M | $-20M | $-10M | $-17.7K | $-45M | $-2M | · | |
| Income Tax | $-1M | · | $0 | · | $0 | $0 | · | |
| Net Income | $-17M | $-20M | $-10M | $-18M | $-45M | $-2M | $-4M | |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | · | · | · | |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | · | · | · | |
| Shares (Basic) | 67,328,128,638 | 23,888,010,485 | 9,788,980,193 | 6,243,462,410 | 852,088,530 | 85,515,588 | 21,075,065 | |
| Shares (Diluted) | 67,328,128,638 | 23,888,010,485 | 9,788,980,193 | 6,243,462,410 | 852,088,530 | 85,515,588 | 21,075,065 | |
| EBITDA | $-17M | $-22M | $-17M | · | $-31M | $-10M | · |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $0 | $4M | $13M | $69M | $3M | $553.7K | |
| Prepaid Expense | $185.0K | $92.0K | $299.0K | $465.0K | $728.1K | $7.8K | · | |
| Other Current Assets | $14.0K | $201.0K | $197.0K | $100.0K | · | · | · | |
| Current Assets | $5M | $3M | $4M | $14M | $70M | $3M | $8M | |
| PP&E (Net) | · | · | · | · | $40.5K | $0 | $0 | |
| PP&E (Gross) | · | · | · | · | · | $67.0K | $10.0K | |
| Goodwill | $8M | $8M | · | · | · | · | · | |
| Intangibles | · | · | $14.0K | $17.0K | $52.5K | $59.4K | · | |
| Total Assets | $48M | $51M | $4M | $14M | $70M | $3M | $8M | |
| Accounts Payable | $9M | $12M | $2M | $947.0K | $4M | $555.5K | · | |
| Accrued Liabilities | $2M | $3M | $2M | $3M | $408.2K | $43.0K | $403.0K | |
| Short-term Debt | $81.0K | $659.0K | · | · | · | · | · | |
| Current Liabilities | $12M | $20M | $5M | · | $21M | $1M | $1M | |
| Deferred Tax | $7M | $8M | · | · | · | · | · | |
| Other Non-current Liabilities | $31.0K | $383.0K | · | · | · | $33.0K | $0 | |
| Total Liabilities | $20M | $28M | $5M | $12M | $21M | $1M | · | |
| Total Debt | $81.0K | $659.0K | · | · | · | · | · | |
| Common Stock | · | $5M | $1M | $745.0K | $18M | $11M | $675.0K | |
| Paid-in Capital | $234M | $213M | · | · | · | · | · | |
| Retained Earnings | $-265M | $-247M | $-227M | $-217M | $-57M | $-11M | $-21M | |
| AOCI | $-782.0K | $-738.0K | $-1M | $-771.0K | $156.5K | $46.1K | $-33.4K | |
| Stockholders' Equity | $28M | $22M | $-229.0K | $2M | $49M | $2M | $400.7K | |
| Liabilities + Equity | $48M | $51M | $4M | $14M | $70M | $3M | $8M | |
| Shares Outstanding | 90,536,879,533 | 53,186,919,523 | 13,234,315,298 | 7,444,917,123 | 1,177,693,383 | 722,345,600 | 40,227,953 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | $14.0K | $4.0K | $4.0K | · | · | · | |
| Stock-based Comp | $3M | $2M | $1M | $735.0K | $1M | $0 | $94.0K | |
| Deferred Tax | $-1M | · | · | · | · | · | · | |
| Restructuring | $-50.0K | $2M | · | · | · | · | · | |
| Other Non-cash | · | $5M | $-8M | · | · | · | · | |
| Operating Cash Flow | $-11M | $-13M | $-16M | $-22M | $-5M | $-1M | $-5M | |
| CapEx | · | · | · | · | $10.6K | $0 | $0 | |
| Investing Cash Flow | · | $382.0K | · | · | $1M | $0 | $0 | |
| Stock Issued | $11M | $12M | $7M | $25M | $75M | $4M | $0 | |
| Net Stock Activity | $11M | $12M | $7M | · | $75M | $0 | · | |
| Financing Cash Flow | $13M | $11M | $7M | $25M | $69M | $4M | $12M | |
| Net Change in Cash | $3M | $-1M | $-9M | $4M | $66M | $3M | $7M | |
| Free Cash Flow | · | · | · | · | $-5M | $-10M | · | |
| Levered FCF | · | · | · | · | $-8M | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| ROA | -35.1% | -72.1% | -110.1% | · | -123.7% | -134.8% | · | |
| ROE | -64.1% | -254.8% | 125100.0% | · | -177.9% | -126.4% | · | |
| ROIC | -57.5% | -94.6% | 7338.9% | · | -62.8% | · | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.1 | · | · | 3.3 | 4.7 | · | |
| Quick Ratio | 0.0 | 0.1 | · | · | 3.3 | 4.6 | · | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | · | · | |
| Interest Coverage | -172.8 | · | · | · | -10.0 | · | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.00 | $0.00 | $0.00 | · | $0.04 | $0.09 | · | |
| Cash Flow / Share | $-0.00 | $-0.00 | $-0.00 | · | $-0.01 | $-0.17 | · | |
| Cash / Share | $0.00 | $0.00 | $0.00 | · | $0.06 | $0.11 | · | |
| EPS (TTM) | $0.00 | $0.00 | $0.00 | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-17M | $-20M | $-10M | · | $-45M | $-2M | · | |
| Market Cap | $26.17B | $64.89B | $41.29B | · | $341.53B | $53.41B | · | |
| Enterprise Value | $26.17B | $64.89B | · | · | · | · | · | |
| P/B | 923.6 | 2919.1 | -180310.3 | · | 7010.1 | 11005.7 | · | |
| P / Tangible Book | 1315.0 | 4702.4 | · | · | · | · | · | |
| P / Cash Flow | -2475.9 | -5169.5 | -2512.8 | · | -68779.7 | -5645.4 | · | |
| P / FCF | · | · | · | · | -68633.7 | -5611.6 | · | |
| EV / EBITDA | -1514.6 | -3000.0 | · | · | · | · | · | |
| Earnings Yield | 0.00% | 0.00% | 0.00% | · | · | · | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2016 | Q4 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $2M | $1M | $1M | $249.0K | $667.0K | $813.0K | $1M | $143.0K | $3M | $2M | $3M | $-314.0K | $2M | $2M | $1M | $3M | |
| SG&A Expense | $3M | $2M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $4M | $3M | $3M | $3M | $3M | $2M | $1M | |
| Operating Expenses | · | $16M | · | · | · | $4M | · | · | · | $6M | · | · | · | · | $4M | $4M | |
| Operating Income | $-5M | $-16M | $-3M | $-7M | $-3M | $-4M | $-5M | $-3M | $-7M | $-6M | $-5M | $-3M | $-5M | $-5M | $-4M | $-4M | |
| Interest Expense | · | · | $0 | $100.0K | · | · | · | · | $51.0K | · | · | · | · | · | $0 | $-6.0K | |
| Interest Income | · | · | $0 | $1.0K | · | · | $1.0K | $3.0K | $2.0K | $2.0K | $7.0K | $16.0K | $29.0K | $30.0K | $30.8K | $19.3K | |
| Other Non-op | $-205.0K | $444.0K | $-2M | $-84.0K | $1M | $-180.0K | $2M | $32.0K | $-109.0K | $-2.0K | $27.0K | $-22.0K | $-13.0K | $-11.0K | $866.6K | $11M | |
| Pretax Income | $-5M | $-15M | $-5M | $-7M | $-2M | $-4M | $-4M | $-3M | · | · | · | · | · | · | $-3M | $7M | |
| Income Tax | · | $-859.0K | $85.0K | $-1M | · | · | · | · | · | $0 | · | · | · | · | $0 | $0 | |
| Net Income | $-5M | $-14M | $-5M | $-6M | $-2M | $-4M | $-4M | $-3M | $-8M | $-6M | $-4M | $-3M | $-4M | $1M | $-3M | $7M | |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | · | · | |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | · | · | |
| Shares (Basic) | 143,317,469,445 | 118,757,013,401 | · | 65,326,236,698 | 62,943,895,665 | 54,588,283,841 | · | 24,386,005,523 | 18,836,478,977 | 13,453,147,979 | · | 10,116,903,598 | 10,115,005,727 | 7,474,546,753 | 1,177,693,383 | · | |
| Shares (Diluted) | 143,317,469,445 | 118,757,013,401 | · | 65,326,236,698 | 62,943,895,665 | 54,588,283,841 | · | 24,386,005,523 | 18,836,478,977 | 13,453,147,979 | · | 10,116,903,598 | 10,115,005,727 | 7,573,542,457 | 1,177,693,383 | · | |
| EBITDA | $-5M | $-16M | · | $-7M | $-3M | $-4M | · | $-3M | $-7M | $-6M | · | · | · | · | $-4M | · |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2016 | Q4 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8M | $3M | $0 | $2M | $3M | $3M | $0 | $2M | $4M | $1M | $4M | · | · | · | $61M | $69M | |
| Prepaid Expense | $532.0K | $731.0K | $185.0K | $349.0K | $447.0K | $627.0K | $92.0K | $396.0K | $805.0K | $1M | $299.0K | · | · | · | $1M | $728.1K | |
| Other Current Assets | $38.0K | $30.0K | $14.0K | $53.0K | $83.0K | $80.0K | $201.0K | $92.0K | $94.0K | $232.0K | $197.0K | · | · | · | · | · | |
| Current Assets | $8M | $4M | $5M | $3M | $3M | $3M | $3M | $3M | $5M | $3M | $4M | · | · | · | $63M | $70M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $74.8K | $40.5K | |
| Goodwill | · | · | $8M | $8M | $8M | $8M | $8M | · | · | · | · | · | · | · | · | · | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | $14.0K | · | · | · | $49.0K | $52.5K | |
| Total Assets | $39M | $34M | $48M | $45M | $51M | $51M | $51M | $3M | $5M | $3M | $4M | · | · | · | $63M | $70M | |
| Accounts Payable | $9M | $9M | $9M | $11M | $12M | $13M | $12M | $5M | $5M | $3M | $2M | · | · | · | $625.4K | $4M | |
| Accrued Liabilities | $4M | $3M | $2M | $2M | $2M | $3M | $3M | $3M | $2M | $2M | $2M | · | · | · | $231.9K | $408.2K | |
| Short-term Debt | · | $49.0K | $81.0K | $198.0K | $179.0K | $228.0K | $659.0K | $200.0K | $600.0K | $900.0K | · | · | · | · | · | · | |
| Current Liabilities | $14M | $13M | $12M | $16M | $17M | $21M | $20M | $9M | $9M | $6M | $5M | · | · | · | $17M | $21M | |
| Deferred Tax | $6M | $6M | $7M | $7M | $8M | $8M | $8M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | $31.0K | $69.0K | $128.0K | $266.0K | $383.0K | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $20M | $20M | $20M | $23M | $25M | $29M | $28M | · | · | · | $5M | · | · | · | $17M | $21M | |
| Total Debt | · | $49.0K | · | $198.0K | $179.0K | $228.0K | · | $200.0K | $600.0K | $900.0K | · | · | · | · | · | · | |
| Common Stock | $1.0K | · | · | $7M | $7M | $6M | $5M | $2M | $2M | $2M | $1M | · | · | · | $18M | $18M | |
| Paid-in Capital | $244M | $235M | $234M | $224M | $221M | · | $213M | · | · | · | · | · | · | · | · | · | |
| Retained Earnings | $-284M | $-279M | $-265M | $-259M | $-253M | $-251M | $-247M | $-243M | $-241M | $-233M | $-227M | · | · | · | $-60M | $-57M | |
| AOCI | $-695.0K | $-768.0K | $-782.0K | $-1M | $-1M | $-773.0K | $-738.0K | $-926.0K | $-749.0K | $-761.0K | $-1M | · | · | · | $-36.5K | $156.5K | |
| Stockholders' Equity | $19M | $14M | $28M | $23M | $26M | $22M | $22M | $-7M | $-4M | $-4M | $-229.0K | · | · | · | $46M | $49M | |
| Liabilities + Equity | $39M | $34M | $48M | $45M | $51M | $51M | $51M | $3M | $5M | $3M | $4M | · | · | · | $63M | $70M | |
| Shares Outstanding | 140,032,769,533 | 91,567,009,533 | 90,536,879,533 | 65,229,461,523 | 65,229,461,523 | 57,752,981,523 | 53,186,919,523 | 24,289,231,523 | 24,289,232,698 | 15,973,121,298 | 13,234,315,298 | · | · | · | 1,177,693,383 | 1,177,693,383 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2016 | Q4 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | $1.0K | $0 | $0 | $13.0K | $1.0K | $1.0K | $1.0K | $1.0K | · | · | |
| Stock-based Comp | $711.0K | $305.0K | $471.0K | $685.0K | $719.0K | $1M | $1M | $248.0K | $445.0K | $296.0K | $304.0K | $305.0K | $276.0K | $265.0K | $816.8K | $963.8K | |
| Deferred Tax | $0 | $-859.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | $-100.0K | $0 | $100.0K | $-50.0K | $3M | $-3M | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $1M | · | · | · | · | · | · | |
| Operating Cash Flow | $-3M | $-2M | $-3M | $-2M | $-3M | $-2M | $-2M | $-1M | $-5M | $-4M | $-4M | $-2M | $-5M | $-5M | $-7M | $-7M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $42.1K | · | |
| Investing Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-42.1K | $-18.8K | |
| Stock Issued | · | · | $5M | $0 | $4M | $1M | $3M | $-133.0K | $7M | $2M | $4M | $0 | $290.0K | $3M | · | $0 | |
| Net Stock Activity | · | · | · | · | · | $2M | · | · | · | $2M | · | · | · | · | · | · | |
| Financing Cash Flow | $8M | $53.0K | $6M | $2M | $3M | $2M | $2M | $-443.0K | $8M | $2M | $4M | $0 | $291.0K | $3M | · | $-3M | |
| Net Change in Cash | $5M | $-2M | $3M | $-227.0K | $129.0K | $-17.0K | $413.0K | $-2M | $3M | $-3M | $-886.0K | $-2M | $-4M | $-2M | $-7M | $-10M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-7M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-7M | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2016 | Q4 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -10.7% | -34.1% | · | -26.6% | -6.8% | -13.8% | · | -7.1% | -188.1% | -16.9% | · | · | · | · | -8.9% | · | |
| ROE | -21.8% | -80.0% | · | -80.0% | -17.3% | -40.7% | · | -16.7% | 553.7% | -26.0% | · | · | · | · | -12.2% | · | |
| ROIC | · | -103.1% | · | -27.7% | · | · | · | · | · | · | · | · | · | · | -8.3% | · |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2016 | Q4 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.6 | 0.4 | · | · | · | · | 3.8 | · | |
| Quick Ratio | 0.6 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.5 | 0.2 | · | · | · | · | 3.7 | · | |
| Debt / Equity | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | -0.0 | -0.2 | -0.3 | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | -74.0 | · | · | · | · | -146.1 | · | · | · | · | · | · | · |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2016 | Q4 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $-0.00 | $-0.00 | $-0.00 | · | · | · | · | $0.04 | · | |
| Cash Flow / Share | · | $0.00 | · | · | · | $0.00 | · | · | · | $-0.00 | · | · | · | · | $-0.01 | · | |
| Cash / Share | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | · | · | · | $0.05 | · | |
| EPS (TTM) | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q1 2016 | Q4 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-31M | $-28M | · | $-16M | $-12M | $-18M | · | $-20M | $-20M | $-17M | · | · | · | · | $-47M | · | |
| Market Cap | $1.43T | $471.57B | · | $65.88B | $76.32B | $71.61B | · | $71.65B | $65.58B | $29.79B | · | · | · | · | $329.75B | · | |
| Enterprise Value | · | $471.57B | · | $65.88B | $76.32B | $71.61B | · | $71.65B | $65.58B | $29.79B | · | · | · | · | · | · | |
| P/B | 77151.7 | 32793.5 | · | 2903.9 | 2980.6 | 3293.2 | · | -10704.1 | -17710.2 | -8384.4 | · | · | · | · | 7113.2 | · | |
| P / Tangible Book | 77151.7 | 32793.5 | · | 4621.0 | 4443.6 | 5378.0 | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -189537.8 | · | · | · | -33308.7 | · | · | · | -7366.4 | · | · | · | · | -44318.4 | · | |
| Earnings Yield | 0.00% | 0.00% | · | 0.00% | 0.00% | 0.00% | · | 0.00% | 0.00% | 0.00% | · | · | · | · | · | · |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2015-12-31 |
|---|---|---|---|---|---|
| Utile netto | $-17M | $-20M | $-10M | $-18M | $-45M |
| EPS Diluito | $0.00 | $0.00 | $0.00 | $0.00 | · |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2015-12-31 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.0 | 0.0 | · | · | · |
| Rapporto corrente | 0.4 | 0.1 | · | · | 3.3 |
| Quick Ratio | 0.0 | 0.1 | · | · | 3.3 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2015-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | · | · | · | · | $-5M |
Proprietari istituzionali (13F) 1 filer · $6K totale · Aggiornato al 31 Dicembre 2025
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
1
Valore detenuto
$6K
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| Skyview Financial Group LLC | $5.946 | 20.575 | 100,00% | Azioni |
Attivisti e proprietari del 5%+ 6 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Samir R. Patel | 04 Marzo 2026 | 10,40% | Modifica | · | SEC |
| Ray Prudo, M.D., RPC Pharma Limited, Praxis Trustees Limited as trustee of the Sonic Healthcare Holding Company ×7 depositi | 04 Marzo 2026 | 0,87% | Modifica | · | SEC |
| Samir R. Patel (2) ×2 depositi | 06 Dicembre 2024 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 18 Giugno 2024 | · | Deposito iniziale | · | SEC |
| Praxis Trustees Limited As trustee of The Sonic Healthcare Holding Company, RPC Pharma Limited, Ray Prudo, M.D. | 18 Ottobre 2021 | · | Deposito iniziale | · | SEC |
| RPC Pharma Limited, Ray Prudo, M.D. ×3 depositi | 30 Marzo 2020 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 24 insider · 9 dirigenti · 19 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Abizer Gaslightwala | CEO | 29 Settembre 2026 A | 14.107 | 2 | 0 | $433.060 |
| Rachelle Suzanne Jacques | Chief Executive Officer | 26 Aprile 2024 A | 1.018.027.792 | 0 | 0 | $0 |
| Gur Roshwalb | Chief Executive Officer | 21 Settembre 2015 A | · | 0 | 0 | $0 |
| Kameel D. Farag | Interim CFO | 17 Agosto 2026 A | 23.309 | 1 | 0 | $9.898 |
| Torsten Hombeck | CFO | 20 Marzo 2025 A | 200 | 0 | 0 | $0 |
| Wendy F Dicicco | Interim CFO | 01 Maggio 2024 A | 158.473.915 | 0 | 0 | $0 |
| Dov Elefant | Chief Financial Officer | 21 Settembre 2015 A | · | 0 | 0 | $0 |
| Clive Richardson | COO | 21 Settembre 2015 A | · | 0 | 0 | $0 |
| Robert M Shaw | General Counsel and Secretary | 23 Marzo 2016 A | · | 0 | 0 | $0 |
| Samir R. Patel | Direttore | 07 Luglio 2026 M | 98.241 | 2 | 0 | $340.262 |
| Sandip I Patel | Direttore | 16 Dicembre 2025 P | 496.499 | 2 | 0 | $160.851 |
| Ray Prudo, M.D. | Direttore | 16 Dicembre 2025 P | 2.484.990 | 2 | 0 | $402.127 |
| Robert B Bazemore | Direttore | 16 Dicembre 2025 P | 44.642 | 2 | 0 | $61.865 |
| James R Neal | Direttore | 16 Dicembre 2025 P | 36.271 | 2 | 0 | $2.226 |
| Hoyoung Huh | Direttore | 16 Dicembre 2025 P | 4.695.854 | 2 | 0 | $1.484.780 |
| Mohamed Wa'El Ahmed Hashad | Direttore | 28 Giugno 2024 A | · | 0 | 0 | $0 |
| Michael Grissinger | Direttore | 28 Giugno 2024 A | · | 0 | 0 | $0 |
| Donald A Williams | Direttore | 28 Giugno 2024 A | · | 0 | 0 | $0 |
| David Byrne | Direttore | 29 Giugno 2016 A | · | 0 | 0 | $0 |
| Stuart Ungar | Direttore | 29 Giugno 2016 A | · | 0 | 0 | $0 |
| James Hill | Direttore | 29 Giugno 2016 A | · | 0 | 0 | $0 |
| Mark S Cohen | Direttore | 29 Giugno 2016 A | 1.055.600 | 0 | 0 | $0 |
| Donald Allen Williams | Direttore | 29 Giugno 2016 A | · | 0 | 0 | $0 |
| Allan Shaw | Direttore | 25 Novembre 2015 A | · | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
AKTX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 10 analisti
COMPRA
Target mediano
$27.00
+209,6%
3 30,0%
Acquisto forte
6 60,0%
Compra
1 10,0%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
3 analisti · 2026-10-03Target medio $25.50 +192,4%
← Sotto tutti i target
Prezzo attuale $8.72
Basso$19.50
Media$25.50
Alto$30.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 13, 2026